Established in 1928, UCB has operations in over 40 countries, supported by more than 10,000 staff. They are a global biopharma focused on severe diseases in three therapeutic areas:

Central nervous system
Inflammation
Oncology

Some Facts about UCB:

Leaders in allergy and epilepsy
A world leader in antibody research
13 large and small molecules in clinical development
Over 30 major R&D and commercial partnerships
They are a global R&D, marketing and sales platform with 10 R&D sites across Europe, Japan and the United States.